From Financial Modeling Prep: 2025-01-15 11:06:00

Exelixis (NASDAQ:EXEL) shares rose over 2% today as Truist Securities analysts raised their price target to $42 from $38 with a Buy rating. The increase reflects confidence in the company’s performance and outlook, especially with strong growth potential in flagship products like Cabometyx.

Exelixis has a strong base business anchored by Cabometyx, showing promise in treating neuroendocrine tumors. Analysts adjusted sales expectations, leading to a higher valuation. Despite recent stock gains, analysts see further growth potential due to reliable revenue and upcoming catalysts like Zanza, a next-generation therapy derived from Cabometyx.

Zanza, a next-generation therapy from Cabometyx, has key milestones expected in 2025 that could boost Exelixis’ stock. Analysts believe the company offers stability and upside potential in a volatile biotech market, making it an attractive investment option.



Read more at Financial Modeling Prep:: Exelixis’ Price Target Raised at Truist, Shares Ri…